[1].  Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 May 25;143(21):e984–e1010. doi: 10.1161/CIR.0000000000000973.

[2].  Ullah MI, Tamanna S. Obesity: clinical impact, pathophysiology, complications, and modern innovations in therapeutic strategies. Medicines. 2025;12(3):19. doi: 10.3390/medicines12030019.

[3].  Crasan IM, Tanase M, Delia CE, Gradisteanu-Pircalabioru G, Cimpean A, Ionica E. Metaflammation’s role in systemic dysfunction in obesity: a comprehensive review. Int J Mol Sci. 2025;26(21):10445. doi: 10.3390/ijms262110445.

[4].  Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, Beguinot F. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol. 2020;10:1607. doi: 10.3389/fphys.2019.01607.

[5].  Gnocchi D, Bruscalupi G. Circadian rhythms and hormonal homeostasis: pathophysiological implications. Biology (Basel). 2017;6(1):10. doi: 10.3390/biology6010010.

[6].  Khan S, Duan P, Yao L, Hou H. Shiftwork-mediated disruptions of circadian rhythms and sleep homeostasis cause serious health problems. Int J Genomics. 2018;2018:8576890. doi: 10.1155/2018/8576890.

[7].  Üstündağ H. The P2X7 receptor/NLRP3 inflammasome signaling axis in sepsis: molecular mechanisms, organ-specific pathophysiology, and emerging therapeutic strategies. Purinergic Signal. 2026;22:26. doi: 10.1007/s11302-026-10140-y.

[8].  Zou C, Jiang S, Li H, Zhao K, Cao D, Yang G. The NLRP3 inflammasome: mechanisms of activation, regulation, and therapeutic opportunities. MedComm (2020). 2026;7(3):e70660. doi: 10.1002/mco2.70660.

[9].  Paik S, Kim JK, Silwal P, Sasakawa C, Jo EK. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 2021;18(5):1141–1160. doi: 10.1038/s41423-021-00670-3.

[10].       Civelek E, Ozturk Civelek D, Akyel YK, Kaleli Durman D, Okyar A. Circadian dysfunction in adipose tissue: chronotherapy in metabolic diseases. Biology (Basel). 2023;12(8):1077. doi: 10.3390/biology12081077.

[11].       Morin R, Forest G, Imbeault P. Circadian rhythms revealed: unraveling the genetic, physiological, and behavioral tapestry of the human biological clock and rhythms. Front Sleep. 2025;4:1544945. doi: 10.3389/frsle.2025.1544945.

[12].       Zhao B, Nepovimova E, Wu Q. The role of circadian rhythm regulator PERs in oxidative stress, immunity, and cancer development. Cell Commun Signal. 2025;23(1):30. doi: 10.1186/s12964-025-02040-2.

[13].       McGinnis GR, Young ME. Circadian regulation of metabolic homeostasis: causes and consequences. Nat Sci Sleep. 2016;8:163–173. doi: 10.2147/NSS.S78946.

[14].       Kalsbeek A, La Fleur S, Fliers E. Circadian control of glucose metabolism. Mol Metab. 2014;3(4):372–383. doi: 10.1016/j.molmet.2014.03.002.

[15].       Lee J, Kim MS, Li R, Liu VY, Fu L, Moore DD, Yechoor VK. Loss of Bmal1 leads to uncoupling and impaired glucose-stimulated insulin secretion in β-cells. Islets. 2011;3(6):381–388. doi: 10.4161/isl.3.6.18157.

[16].       Liu M, Zhang Z, Chen Y, Feng T, Zhou Q, Tian X. Circadian clock and lipid metabolism disorders: a potential therapeutic strategy for cancer. Front Endocrinol (Lausanne). 2023;14:1292011. doi: 10.3389/fendo.2023.1292011.

[17].       Boege HL, Bhatti MZ, St-Onge MP. Circadian rhythms and meal timing: impact on energy balance and body weight. Curr Opin Biotechnol. 2021;70:1–6. doi: 10.1016/j.copbio.2020.08.009.

[18].       Mezhnina V, Ebeigbe OP, Poe A, Kondratov RV. Circadian control of mitochondria in reactive oxygen species homeostasis. Antioxid Redox Signal. 2022;37(10–12):647–663. doi: 10.1089/ars.2021.0274.

[19].       Jin Z, Ji Y, Su W, Zhou L, Wu X, Gao L, Guo J, Liu Y, Zhang Y, Wen X, Xia ZY, Xia Z, Lei S. The role of circadian clock-controlled mitochondrial dynamics in diabetic cardiomyopathy. Front Immunol. 2023;14:1142512. doi: 10.3389/fimmu.2023.1142512.

[20].       Potter GDM, Skene DJ, Arendt J, Cade JE, Grant PJ, Hardie LJ. Circadian rhythm and sleep disruption: causes, metabolic consequences, and countermeasures. Endocr Rev. 2016;37(6):584–608. doi: 10.1210/er.2016-1083.

[21].       Khan S, Duan P, Yao L, Hou H. Shiftwork-mediated disruptions of circadian rhythms and sleep homeostasis cause serious health problems. Int J Genomics. 2018;2018:8576890. doi: 10.1155/2018/8576890.

[22].       Arab A, Karimi E, Garaulet M, Scheer FAJL. Social jetlag and obesity: a systematic review and meta-analysis. Obes Rev. 2024;25(3):e13664. doi: 10.1111/obr.13664.

[23].       Papatriantafyllou E, Efthymiou D, Zoumbaneas E, Popescu CA, Vassilopoulou E. Sleep deprivation: effects on weight loss and weight loss maintenance. Nutrients. 2022;14(8):1549. doi: 10.3390/nu14081549.

[24].       Bonilla-Jaime H, Zeleke H, Rojas A, Espinosa-Garcia C. Sleep disruption worsens seizures: neuroinflammation as a potential mechanistic link. Int J Mol Sci. 2021;22(22):12531. doi: 10.3390/ijms222212531.

[25].       Gagliano O, Luni C, Li Y. Synchronization between peripheral circadian clock and feeding-fasting cycles in microfluidic device sustains oscillatory pattern of transcriptome. Nat Commun. 2021;12:6185. doi: 10.1038/s41467-021-26294-9.

[26].       Ella K, Sűdy ÁR, Búr Z, Koós B, Kisiczki ÁS, Mócsai A, Káldi K. Time restricted feeding modifies leukocyte responsiveness and improves inflammation outcome. Front Immunol. 2022;13:924541. doi: 10.3389/fimmu.2022.924541.

[27].       Yang Z, Kim H, Ali A, Zheng Z, Zhang K. Interaction between stress responses and circadian metabolism in metabolic disease. Liver Res. 2017;1(3):156–162. doi: 10.1016/j.livres.2017.11.002.

[28].       Katoku-Kikyo N, Lim S, Yuan C, Koroth J, Nakagawa Y, Bradley EW, et al. The circadian regulator PER1 promotes cell reprogramming by inhibiting inflammatory signaling from macrophages. PLoS Biol. 2023;21(12):e3002419. doi: 10.1371/journal.pbio.3002419.

[29].       Grimaldi B, Bellet MM, Katada S, Astarita G, Hirayama J, Amin RH, Granneman JG, Piomelli D, Leff T, Sassone-Corsi P. PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab. 2010;12(5):509–520. doi: 10.1016/j.cmet.2010.10.005.

[30].       Viola AU, Archer SN, James LM, Groeger JA, Lo JC, Skene DJ, von Schantz M, Dijk DJ. PER3 polymorphism predicts sleep structure and waking performance. Curr Biol. 2007;17(7):613–618. doi: 10.1016/j.cub.2007.01.073.

[31].       Liu Y, Huang Y, Luo H, Lin X. The roles of Cryptochrome-1: the circadian clock as a control point in cancer therapy. J Transl Med. 2025;23(1):669. doi: 10.1186/s12967-025-06702-0.

[32].       Kriebs A, Jordan SD, Soto E, Henriksson E, Sandate CR, Vaughan ME, Chan AB, Duglan D, Papp SJ, Huber A, Afetian ME, Yu RT, Zhao X, Downes M, Evans RM, Lamia KA. Circadian repressors CRY1 and CRY2 broadly interact with nuclear receptors and modulate transcriptional activity. Proc Natl Acad Sci U S A. 2017;114(33):8776–8781. doi: 10.1073/pnas.1704955114.

[33].       Wang J, Wang Y, Lin L, Pei W, Li Y. Rev-erbα: the circadian guardian against NLRP3-driven liver fibrosis. Mol Med Rep. 2025;32(4):270. doi: 10.3892/mmr.2025.13635.

[34].       Adlanmerini M, Lazar MA. The REV-ERB nuclear receptors: timekeepers for the core clock period and metabolism. Endocrinology. 2023;164(6):bqad069. doi: 10.1210/endocr/bqad069.

[35].       Chauvet C, Bois-Joyeux B, Berra E, Pouyssegur J, Danan JL. The gene encoding human retinoic acid-receptor-related orphan receptor α is a target for hypoxia-inducible factor 1. Biochem J. 2004;384(Pt 1):79–85. doi: 10.1042/BJ20040709.

[36].       Liu H, Aramaki M, Fu Y, Forrest D. Retinoid-related orphan receptor β and transcriptional control of neuronal differentiation. Curr Top Dev Biol. 2017;125:227–255. doi: 10.1016/bs.ctdb.2016.11.009.

[37].       Jetten AM, Takeda Y, Slominski A, Kang HS. Retinoic acid-related orphan receptor γ (RORγ): connecting sterol metabolism to regulation of the immune system and autoimmune disease. Curr Opin Toxicol. 2018;8:66–80. doi: 10.1016/j.cotox.2018.01.005.

[38].       Sun H, Li D, Wei C, Liu L, Xin Z, Gao H, Gao R. The relationship between SIRT1 and inflammation: a systematic review and meta-analysis. Front Immunol. 2024;15:1465849. doi: 10.3389/fimmu.2024.1465849.

[39].       Kodi T, Nandakumar K, Kishore A. AMPK–NLRP3 inflammasome crosstalk: structural insights, molecular mechanisms, and therapeutic implications for inflammation and neuroinflammation. Mol Neurobiol. 2026;63(1):684–702. doi: 10.1007/s12035-026-05932-7.

[40].       Rius-Pérez S, Torres-Cuevas I, Millán I, Ortega ÁL, Pérez S, Sandhu MA. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. 2020;2020:1452696. doi: 10.1155/2020/1452696.

[41].       Stojanovic B, Milivojcevic Bevc I, Dimitrijevic Stojanovic M, Stojanovic BS, Jovanovic M, Lazarevic S, Milosevic B, Radosavljevic I, Tasic-Uros D, Markovic N. Nrf2 as a molecular guardian of redox balance and barrier integrity in IBD. Antioxidants. 2025;14:1407. doi: 10.3390/antiox14121407.

[42].       Corcoran SE, O’Neill LAJ. HIF1α and metabolic reprogramming in inflammation. J Clin Invest. 2016;126(10):3699–3707. doi: 10.1172/JCI84431.

[43].       González-Dominguez A, Zhang S, Boy-Ruiz D, Connors D, de la Varga-Martínez R, Mock BA, Cordero MD. mTOR modulates NLRP3 inflammasome activation via nuclear translocation and STAT1 inhibition. Eur J Immunol. 2025;55:e51176. doi: 10.1002/eji.202451176.

[44].       Liu X, Li Y, Huang L, Kuang Y, Wu X, Ma X, Zhao B, Lan J. Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders. Front Pharmacol. 2024;15:1450704. doi: 10.3389/fphar.2024.1450704.

[45].       Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47(1):15–31. doi: 10.1016/j.immuni.2017.06.020.

[46].       Liang W, Qi Y, Yi H, Mao C, Meng Q, Wang H, Zheng C. The roles of adipose tissue macrophages in human disease. Front Immunol. 2022;13:908749. doi: 10.3389/fimmu.2022.908749.

[47].       Xia GQ, Fang Q, Cai JN, Li ZX, Zhang FZ, Lv XW. P2X7 receptor in alcoholic steatohepatitis and alcoholic liver fibrosis. J Clin Transl Hepatol. 2022;10(6):1205–1214. doi: 10.14218/JCTH.2022.00022.

[48].       Giacovazzo G, Fabbrizio P, Apolloni S, Coccurello R, Volonté C. Stimulation of P2X7 enhances whole body energy metabolism in mice. Front Cell Neurosci. 2019;13:390. doi: 10.3389/fncel.2019.00390.

[49].       Le Thuc O, Stobbe K, Cansell C, Nahon JL, Blondeau N, Rovère C. Hypothalamic inflammation and energy balance disruptions: spotlight on chemokines. Front Endocrinol (Lausanne). 2017;8:197. doi: 10.3389/fendo.2017.00197.

[50].       Acuña-Castillo C, Escobar A, García-Gómez M, Bachelet VC, Huidobro-Toro JP, Sauma D, Barrera-Avalos C. P2X7 receptor in dendritic cells and macrophages: implications in antigen presentation and T lymphocyte activation. Int J Mol Sci. 2024;25(5):2495. doi: 10.3390/ijms25052495.

[51].       Dludla PV, Mabhida SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, Basson AK, Pheiffer C, Kengne AP. Pancreatic β-cell dysfunction in type 2 diabetes: implications of inflammation and oxidative stress. World J Diabetes. 2023;14(3):130–146. doi: 10.4239/wjd.v14.i3.130.

[52].       Feng JJ, Maddirala NR, Saint Fleur A, Zhou F, Yu D, Wei F, Zhang Y. Gut microbiome and immune system crosstalk in chronic inflammatory diseases: a narrative review of mechanisms and therapeutic opportunities. Microorganisms. 2025;13(11):2516. doi: 10.3390/microorganisms13112516.

[53].       Wang Y, Deng Z, Li Y, Bai K, Ma J, Liu Y, Chen Q. Function of hematopoiesis and bone marrow niche in inflammation and non-hematopoietic diseases. Life Med. 2025;4(3):lnaf015. doi: 10.1093/lifemedi/lnaf015.

[54].       Strizova Z, Benesova I, Bartolini R, Novysedlak R, Cecrdlova E, Foley LK, Striz I. M1/M2 macrophages and their overlaps – myth or reality? Clin Sci (Lond). 2023;137(15):1067–1093. doi: 10.1042/CS20220531.

[55].       Topchyan P, Lin S, Cui W. The role of CD4 T cell help in CD8 T cell differentiation and function during chronic infection and cancer. Immune Netw. 2023;23(5):e41. doi: 10.4110/IN.2023.23.E41.

[56].       Cieri MB, Ramos AJ. Astrocytes, reactive astrogliosis, and glial scar formation in traumatic brain injury. Neural Regen Res. 2024;20(4):973–983. doi: 10.4103/NRR.NRR-D-23-02091.

[57].       Xu Z, Chen ZM, Wu X, Zhang L, Cao Y, Zhou P. Distinct molecular mechanisms underlying potassium efflux for NLRP3 inflammasome activation. Front Immunol. 2020;11:609441. doi: 10.3389/fimmu.2020.609441.

[58].       Zhang J, Li L, Guo Q, Liu X, Qiao Q, Ye X, et al. ATP-P2X7R-NLRP3 axis as a unifying mechanism of ATP-induced cell death in degenerative bone and cardiovascular diseases. J Inflamm Res. 2026;19. doi: 10.2147/JIR.S584582.

[59].       Kopp R, Krautloher A, Ramírez-Fernández A, Nicke A. P2X7 interactions and signaling – making head or tail of it. Front Mol Neurosci. 2019;12:183. doi: 10.3389/fnmol.2019.00183.

[60].       Wang X, Dong YT, Hu XM. The circadian regulation of extracellular ATP. Purinergic Signal. 2023;19:283–295. doi: 10.1007/s11302-022-09881-3.

[61].       Zheng Z, Yang S, Dai W, Xue P, Sun Y, Wang J, Zhang X, Lin J, Kong J. The role of pyroptosis in metabolism and metabolic disease. Biomed Pharmacother. 2024;176:116863. doi: 10.1016/j.biopha.2024.116863.

[62].       Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137:111315. doi: 10.1016/j.biopha.2021.111315.

[63].       Yuan Q, Zeng ZL, Yang S, Li A, Zu X, Liu J. Mitochondrial stress in metabolic inflammation: modest benefits and full losses. Oxid Med Cell Longev. 2022;2022:8803404. doi: 10.1155/2022/8803404.

[64].       Karin M, Kim JY. Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer. Pharmacol Rev. 2025;77(6):100096. doi: 10.1016/j.pharmrev.2025.100096.

[65].       Ansari WA, Srivastava K, Nasibullah M, Khan MF. Reactive oxygen species (ROS): sources, generation, disease pathophysiology, and antioxidants. Discov Chem. 2025;2(1):191. doi: 10.1007/s44371-025-00275-z.

[66].       Buchynskyi M, Kamyshna I, Halabitska I, Petakh P, Kunduzova O, Oksenych V, Kamyshnyi O. Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease. Front Microbiol. 2025;16:1577724. doi: 10.3389/fmicb.2025.1577724.

[67].       Burdette BE, Esparza AN, Zhu H, Wang S. Gasdermin D in pyroptosis. Acta Pharm Sin B. 2021;11(9):2768–2782. doi: 10.1016/j.apsb.2021.02.006.

[68].       Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011;22(4):189–195. doi: 10.1016/j.cytogfr.2011.10.001.

[69].       Stoess C, Onyuru J, Hartmann P, Hoffman HM, Broderick L, Feldstein AE. Interleukin-18 in obesity and obesity-related metabolic diseases. Nat Rev Endocrinol. 2025;22(1):3–4. doi: 10.1038/s41574-025-01199-5.

[70].       Dai Z, Liu WC, Chen XY, Wang X, Li JL, Zhang X. Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors. Front Immunol. 2023;14:1178662. doi: 10.3389/fimmu.2023.1178662.

[71].       Lu S, Li Y, Qian Z, Zhao T, Feng Z, Weng X, Yu L. Role of the inflammasome in insulin resistance and type 2 diabetes mellitus. Front Immunol. 2023;14:1052756. doi: 10.3389/fimmu.2023.1052756.

[72].       Feng Z, Tan Z, Lu D. Mitochondrial bioenergetics dysfunction in T2DM: linking oxidative stress to insulin resistance. Front Endocrinol (Lausanne). 2025;16:1674477. doi: 10.3389/fendo.2025.1674477.

[73].       Chiarini A, Gui L, Viviani C, Armato U, Dal Prà I. NLRP3 inflammasome’s activation in acute and chronic brain diseases—an update on pathogenetic mechanisms and therapeutic perspectives with respect to other inflammasomes. Biomedicines. 2023;11(4):999. doi: 10.3390/biomedicines11040999.

[74].       Li X, Rothämel P, Nussbaum C, Sperandio M, Scheiermann C. Development of a circadian immune system. Trends Immunol. 2025;46(9):614–623. doi: 10.1016/j.it.2025.06.004.

[75].       de Assis LVM, Oster H. The circadian clock and metabolic homeostasis: entangled networks. Cell Mol Life Sci. 2021;78(10):4563–4580. doi: 10.1007/s00018-021-03800-2.

[76].       Smirnova KV, Smirnova LP, Amstislavskaya TG. Core circadian protein BMAL1: implication for nervous system functioning and its diseases. Brain Sci. 2025;15(12):1321. doi: 10.3390/brainsci15121321.

[77].       Li L, Zhang M, Zhao C, Cheng Y, Liu C, Shi M. Circadian clock gene Clock-Bmal1 regulates cellular senescence in chronic obstructive pulmonary disease. BMC Pulm Med. 2022;22(1):435. doi: 10.1186/s12890-022-02237-y.

[78].       Zhao B, Nepovimova E, Wu Q. The role of circadian rhythm regulator PERs in oxidative stress, immunity, and cancer development. Cell Commun Signal. 2025;23(1):30. doi: 10.1186/s12964-025-02040-2.

[79].       Gerhart-Hines Z, Lazar MA. Rev-erbα and the circadian transcriptional regulation of metabolism. Diabetes Obes Metab. 2015;17(Suppl 1):12–17. doi: 10.1111/dom.12510.

[80].       Lee JM, Kim H, Baek SH. Unraveling the physiological roles of retinoic acid receptor-related orphan receptor α. Exp Mol Med. 2021;53(9):1278–1290. doi: 10.1038/s12276-021-00679-8.

[81].       Andrejew R, Oliveira-Giacomelli Á, Ribeiro DE, Glaser T, Arnaud-Sampaio VF, Lameu C, Ulrich H. The P2X7 receptor: central hub of brain diseases. Front Mol Neurosci. 2020;13:124. doi: 10.3389/fnmol.2020.00124.

[82].       Zhang W, Qi D, Pei X. Circadian disruption and ROS-NLRP3 signaling mediate sleep deprivation-enhanced silica nanoparticle toxicity in lacrimal glands. J Nanobiotechnol. 2025;23:600. doi: 10.1186/s12951-025-03630-5.

[83].       Pourcet B, Duez H. Circadian control of inflammasome pathways: implications for circadian medicine. Front Immunol. 2020;11:1630. doi: 10.3389/fimmu.2020.01630.

[84].       Palma G, Sorice GP, Genchi VA, Giordano F, Caccioppoli C, D’Oria R, Marrano N, Biondi G, Giorgino F, Perrini S. Adipose tissue inflammation and pulmonary dysfunction in obesity. Int J Mol Sci. 2022;23:7349. doi: 10.3390/ijms23137349.

[85].       Richard AJ, White U, Elks CM, Stephens JM. Adipose tissue: physiology to metabolic dysfunction. Endotext. 2020 Apr. No DOI.

[86].       Yu L, Hong W, Lu S, Li Y, Guan Y, Weng X, Feng Z. The NLRP3 inflammasome in non-alcoholic fatty liver disease and steatohepatitis: therapeutic targets and treatment. Front Pharmacol. 2022;13:780496. doi: 10.3389/fphar.2022.780496.

[87].       Yeung AY, Tadi P. Physiology, obesity neurohormonal appetite and satiety control. StatPearls. 2023 Jan. No DOI.

[88].       Timper K, Brüning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017;10(6):679–689. doi: 10.1242/dmm.026609.

[89].       Dyar KA, Ciciliot S, Wright LE, Biensø RS, Tagliazucchi GM, Patel VR, Forcato M, Paz MIP, Gudiksen A, Solagna F, Albiero M, Moretti I, Eckel-Mahan KL, Baldi P, Sassone-Corsi P, Rizzuto R, Bicciato S, Pilegaard H, Blaauw B, Schiaffino S. Muscle insulin sensitivity and glucose metabolism are controlled by the intrinsic muscle clock. Mol Metab. 2014;3(1):29–41. doi: 10.1016/j.molmet.2013.10.005.

[90].       Merz KE, Thurmond DC. Role of skeletal muscle in insulin resistance and glucose uptake. Compr Physiol. 2020;10(3):785–809. doi: 10.1002/cphy.c190029.

[91].       Zhang M, Zhou C, Li X, Li H, Han Q, Chen Z, Tang W, Yin J. Interactions between gut microbiota, host circadian rhythms, and metabolic diseases. Adv Nutr. 2025;16(6):100416. doi: 10.1016/j.advnut.2025.100416.

[92].       O'Siorain JR, Cox SL, Payet C, Nally FK, He Y, Drewinksi TT, Kennedy OD, Dowling JK, Mellett M, Early JO, Curtis AM. Time-of-day control of mitochondria regulates NLRP3 inflammasome activation in macrophages. FASEB J. 2024;38(24):e70235. doi: 10.1096/fj.202400508RR.

[93].       Chen F, Yang H, Fu X, Liu Z, Chen Y, Xu T, Chen Z, Luo X, Wang C, Guo Y. Research progress of BMAL1 in heart failure. J Am Heart Assoc. 2025;14(20):e043244. doi: 10.1161/JAHA.125.043244.

[94].       Noh J. The effect of circadian and sleep disruptions on obesity risk. J Obes Metab Syndr. 2018;27(2):78–87. doi: 10.7570/JOMES.2018.27.2.78.

[95].       Atchou K, Madalageri M, Manandhar S, Pai KSR. Targeting P2X7 receptor/NLRP1 inflammasome axis and gut dysbiosis: a mechanistic review of pyroptosis in metabolic inflammation. Exp Mol Pathol. 2026;146:105041. doi: 10.1016/j.yexmp.2026.105041.

[96].       Coll RC, Hill JR, Day CJ. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol. 2019;15:556–559. doi: 10.1038/s41589-019-0277-7.

[97].       Satyam SM, Prabhakar S, El-Tanani M, Bhongade B, Wali AF, Rangraze IR, Matalka IIA, El-Tanani Y, Rizzo M, Ispas S, Ilias I, Paczkowska A, Maggio V, Hoffmann K. Chronopharmacology-driven precision therapies for time-optimized cardiometabolic disease management. Biology (Basel). 2026;15(3):241. doi: 10.3390/biology15030241.

[98].       Mandal S, Simmons N, Awan S, Chamari K, Ahmed I. Intermittent fasting: eating by the clock for health and exercise performance. BMJ Open Sport Exerc Med. 2022;8(1):e001206. doi: 10.1136/bmjsem-2021-001206.

[99].       Kim HK, Radak Z, Takahashi M, Inami T, Shibata S. Chrono-exercise: time-of-day-dependent physiological responses to exercise. Sports Med Health Sci. 2023;5(1):50–57. doi: 10.1016/j.smhs.2022.11.003.

[100].    Hesketh SJ. Resetting time: the role of exercise timing in circadian reprogramming for metabolic health. Obesities. 2025;5(3):59. doi: 10.3390/obesities5030059.

[101].    Alum EU. Circadian nutrition and obesity: timing as a nutritional strategy. J Health Popul Nutr. 2025;44(1):367. doi: 10.1186/s41043-025-01102-y.

[102].    Tosti V, Bertozzi B, Fontana L. Health benefits of the Mediterranean diet: metabolic and molecular mechanisms. J Gerontol A Biol Sci Med Sci. 2017;73(3):318–326. doi: 10.1093/gerona/glx227.

[103].    Reytor-González C. Chrononutrition and energy balance: how meal timing and circadian rhythms shape weight regulation and metabolic health. Nutrients. 2025;17(13):2135. doi: 10.3390/nu17132135.

[104].    Chandrasekaran P, Weiskirchen S, Weiskirchen R. Effects of probiotics on gut microbiota: an overview. Int J Mol Sci. 2024;25(11):6022. doi: 10.3390/ijms25116022.

[105].    Bedu-Ferrari C, Biscarrat P, Langella P, Cherbuy C. Prebiotics and the human gut microbiota: from breakdown mechanisms to the impact on metabolic health. Nutrients. 2022;14(10):2096. doi: 10.3390/nu14102096.

[106].    Espinosa-Salas S, Keyes D, Gonzalez-Arias M. Behavior modification for lifestyle improvement. StatPearls. 2026 May. No DOI.

[107].    Kim DW, Zavala E, Kim JK. Wearable technology and systems modeling for personalized chronotherapy. Curr Opin Syst Biol. 2020;21:9–15. doi: 10.1016/j.coisb.2020.07.007.

[108].    Chen P, Wang Y, Yuan M, Li X, Li Z, Li C, Li K. Chrono-nutrition in precision nutrition: integrating chronotype into personalized dietary interventions. J Adv Res. 2026. doi: 10.1016/j.jare.2026.03.006.

[109].    Arabi S, Ahmad S. Time matters: chrono-pharmacotherapy as precision medicine. Asia Pac J Pharmacother Toxicol. 2025. doi: 10.32948/AJPT.2025.01.20.

[110].    Xu M, Yu Y, Li L, Zhao K, Lai J, Wei L, Ge L. Rhein ameliorates inflammation, gut dysbiosis, and renal injury in obesity-related glomerulopathy mice. Front Pharmacol. 2025;16:1654062. doi: 10.3389/fphar.2025.1654062.

[111].    Yang M, Liu S, Zhang C. The related metabolic diseases and treatments of obesity. Healthcare (Basel). 2022;10(9):1616. doi: 10.3390/healthcare10091616.

[112].    Lin A, Ding Y, Li Z, Jiang A, Liu Z, Wong HZH, Cheng Q, Zhang J, Luo P. Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence. Biomark Res. 2025;13(1):50. doi: 10.1186/s40364-025-00765-3.

[113].    Zeeshan M, Hu J, Mao CX, Danish A, Xiong Y, Irshad MS, Dao VD, Liu Z. Nanomaterial-enabled drug delivery systems for circadian medicine: bridging direct rhythm modulation and chronotherapy. RSC Adv. 2025;15(38):31981–32008. doi: 10.1039/D5RA04137F.

[114].    Wang L, Jia Q, He J, Li Y. Adipose tissue-targeting nanomedicines for obesity pharmacotherapy. Trends Endocrinol Metab. 2025;36(12):1127–1139. doi: 10.1016/j.tem.2025.03.010.

[115].    Svobodova I, Bhattaracharya A, Ivetic M, Bendova Z, Zemkova H. Circadian ATP release in organotypic cultures of the rat suprachiasmatic nucleus is dependent on P2X7 and P2Y receptors. Front Pharmacol. 2018;9:192. doi: 10.3389/fphar.2018.00192.

[116].    Pandey A, Kothari A, Kar SK. Sleep and circadian rhythm in peripheral inflammation: realm of interconnected frontiers. In: Jha PK, Bouaouda H, editors. Circadian Rhythms, Sleep and Inflammation. Progress in Inflammation Research. Vol. 93. Cham: Springer; 2024. doi: 10.1007/978-3-031-74744-1_4.

[117].    Kaşkal M, Sevim M, Ülker G, Keleş C, Bebitoğlu BT. The clinical impact of chronopharmacology on current medicine. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(6):6179–6191. doi: 10.1007/s00210-025-03788-7.

[118].    Ramachandran R, Manan A, Kim J, Choi S. NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders. Exp Mol Med. 2024;56(7):1488–1503. doi: 10.1038/s12276-024-01261-8.

[119].    Reddy S, Reddy V, Sharma S. Physiology, circadian rhythm. StatPearls. 2023 May. No DOI.

[120].    Xu Q, Lin A, Jiang A. Circadian rhythms as a modulator of gut microbiota-tumor microenvironment crosstalk. Cell Mol Life Sci. 2025;82:409. doi: 10.1007/s00018-025-05935-y.